Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis

Breast Cancer

Volumn 23, Issue 6, 2016, Pages 876-885

  Imamura, Takahisa ^a   Yamamoto Ibusuki, Mutsuko ^a   Sueta, Aiko ^a   Kubo, Tatsuko ^a   Irie, Atsushi ^a   Kikuchi, Ken ^b   Kariu, Toru ^c   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c Kumamoto University   (Japan)

Author keywords

C5a; C5a receptor; Lymph node metastasis; Prognosis; Proliferation

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; C5AR1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPLEMENT C5A; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ANAPHYLATOXIN C5A; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84944936799     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-015-0654-3     Document Type: Article

References (42)

1. Siegel R, Naishadham MA, Jemal ADV. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of BC: two, three, four, or more ? J Natl Cancer Inst. 2014;106(8):dju165. doi:10.1093/jnci/dju165.
3. Gucalp A, Traina TA. Triple-negative BC: adjuvant therapeutic options. Chemother Res Prac 2011;696208. doi:10.1155/2011/696208.
4. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–92.
5. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, et al. Clinicopathological analyses of triple negative breast cancer using surveyance data from the Registration Committee of the Japanese breast cancer society. Breast Cancer. 2010;17:118–24.
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative BC. Clinical features and patterns of recurrence. Cin Cancer Res. 2007;13:4429–34.
7. DiScipio RG, Smith CA, Müller-Eberhard HJ, Hugli TE. The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem. 1983;258:10629–36.
8. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821–52.
9. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171:715–27.
10. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in BC. Am J Pathol. 1992;140:1039–43.
11. Bjørge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE, et al. Ascitic complement system in ovarial cancer. Br J Cancer. 2005;92:895–905.
12. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–35.
13. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 2012;186:4674–83.
14. Nitta H, Murakami Y, Wada Y, Eto M, Baba H, Imamura T. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep. 2014;32:1715–9.
15. Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 2013;19:2004–13.
16. Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, K1-67 and the corresponding gene expression score in breast cancer. Modern Pathol. 2013;26:79–86.
17. −ΔΔCTmethod. Methods. 2001;25:402–8.
18. Finn RS, Dering J, Conklin D, Kalous O, Cohen D, Desai A, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
19. van de Vijer MJ. Molecular tests as prognostic factors in breast cancer. Virchows Arch. 2014;464:283–91.
20. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11:643–58.
21. Valabrega G, Montemurro F, Sarotto I, Petorelli A, Rubini P, Tacchetti C, et al. TGFα expression impairs trastuzumab-induced HER2 downregulation. Oncogene. 2005;24:3002–10.
22. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121:3797–803.
23. Gu J, Ding J-Y, Lu C-L, Lin Z-W, Chu Y-W, Zhao G-Y, et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013;81:259–65.
24. Cai K, Wan Y, Wang Z, Wang Y, Zhao XJ, Bao XL. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation. Oncol Rep. 2014;32:2260–6.
25. Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T. Relation of anaphylatoxin C5a receptor (CD88) expression of urothelial cancer to poor prognosis of patients treated by radical cystectomy or nephro-ureterectomy. Oncol Lett 2015
26. (in press).
27. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014;6:1–11.
28. Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol. 1994;12:775–808.
29. Müller A, Homey H, Soto H, Ge N, Carton D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.
30. Roland J, Murphy BJ, Ahr B, Robert-Hebmann V, Delauzun V, Ke Nye, et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood. 2003;101:399–406.
31. Sun X, Wei L, Chen Q, Terek RM. CXCR4/SDF-1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer. 2010;9:17.
32. Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep. 2015;33:1844–50.
33. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967–71.
34. Sobolik T, Sun YJ, Wells S, Ayers GD, Cook RS, Richmond A. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3 pathways. Mol Biol Cell. 2014;25:566–82.
35. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24:7443–54.
36. Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The elevated levels of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast. 2005;14:360–7.
37. Su YC, Wu MT, Huang CJ, Hou MF, Yang SF, Chai CY. Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. The Breast. 2006;15:533–9.
38. Hasaan S, Buchanan M, Jahan K, Aguila-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011;129:225–32.
39. Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, et al. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS ONE. 2013;8:e58426.
40. Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastasis. Proc Natl Acad Sci USA. 2013;110:E1291–300.
41. +T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175:4583–92.
42. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrons mediate the initial angiogenic switch in a mouse model of multi-stage carcinogenesis. Proc Natl Acad Sci USA. 2006;103:12493–8.